Recently, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have been successful in clinical use in regulating glucose metabolism in diabetes mellitus patients apart from other therapies like insulin, sulfonylureas, biguanides, meglitinides, thiazolidinediones, and alpha-glucosidase inhibitors [10]. This evidence concerns the gene INS and diabetes mellitus.